Invezz

IQVIA Holdings Inc (IQV)

NYSE Market Closed

IQVIA Holdings Inc. provides data, analytics, technology, and outsourced research services to the global life sciences industry. The company was created through the 2016 combination of Quintiles, a major clinical research organisation, and IMS Health, a healthcare information and analytics specialist. That merger gave IQVIA a distinctive position at the intersection of clinical development, real-world healthcare data, and commercial execution.

Its Research & Development Solutions business helps biopharmaceutical companies plan and run clinical programmes. Services can cover trial design, patient recruitment, site selection and management, clinical monitoring, laboratory and testing support, real-world evidence studies, and assistance with regulatory processes. By outsourcing this work to IQVIA, drug developers can access global infrastructure, therapeutic expertise, and operational scale without building every capability internally.

IQVIA also supports companies after and around product launch through its technology and commercial services. These offerings include healthcare analytics, market access support, sales and medical outsourcing, and software platforms used to understand treatment patterns, physician behaviour, patient populations, and product performance. The company’s data assets and analytical tools are used by pharmaceutical manufacturers, biotechnology companies, medical technology firms, payers, providers, and public-sector organisations.

The company’s role is tied closely to the complexity of modern healthcare. Drug development requires larger data sets, more specialised trial designs, and stronger evidence of safety, efficacy, value, and real-world outcomes. IQVIA serves that demand by combining contract research capabilities with healthcare intelligence, making it a key service provider for companies seeking to develop, approve, and commercialise medicines globally.

208.05 USD
+0.73 (+0.35%)

Last updated

Market Cap
$34,723,545,000
P/E
25.07
P/FCF
16.41
P/S
2.09
Enterprise Value
$48,609,545,000
Sector
Health Care
Industry
Life Sciences Tools & Services
Address
2400 ELLIS ROAD, DURHAM, NC, 27703
globenewswire.com

Pharmacovigilance Automation Market Size to Reach USD 5.25 Billion by 2035 | SNS Insider

24 Jun 2026, 12:30 PM
globenewswire.com

Global Decentralized Clinical Trials Market Size/Share Worth USD 38.3 Billion by 2035 at a 14.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

22 Jun 2026, 23:30 PM
globenewswire.com

Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China

11 May 2026, 15:00 PM
globenewswire.com

Clinical Trial Management System Research Report 2026: $4.2 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

24 Apr 2026, 13:56 PM
globenewswire.com

Clinical Trial Data Visualization Research Report 2026: $1.82 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

24 Apr 2026, 13:53 PM
globenewswire.com

Clinical Trials Support Software Solutions in a $34.15B Trial Economy by 2035

18 Feb 2026, 19:00 PM
globenewswire.com

Why Clinical Data Analytics Is Becoming One of Healthcare’s Fastest-Growing Markets?

19 Jan 2026, 19:00 PM
globenewswire.com

$1.55 Bn Disease Registry Software Global Markets, 2019-2024, 2024-2029F, 2034F: Shift to Value-based Care and Addressing Rare Diseases Offer Further Growth Avenues

12 Jan 2026, 20:00 PM
globenewswire.com

Electronic Clinical Outcome Assessment Solutions Market Projected to Reach USD 5.64 Billion by 2032 at a CAGR of 15.3% - SNS Insider

14 Dec 2025, 17:10 PM
globenewswire.com

Certara Appoints Jon Resnick as Chief Executive Officer

11 Dec 2025, 15:00 PM
globenewswire.com

Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response

04 Dec 2025, 22:47 PM
globenewswire.com

Generic Drug CRO Market Size to Climb to USD 11.73 Billion by 2034, reports Towards Healthcare

25 Nov 2025, 16:00 PM
globenewswire.com

Real World Evidence Solutions Research and Forecast Report 2025-2030: Growth Opportunities in Emerging Markets and Increased Focus on End-To-End Rwe Services, & Personalized and Precision Medicine

01 Oct 2025, 18:00 PM
Market Cap
$34,723,545,000
Enterprise Value
$48,609,545,000
P/E
25.07
P/B
5.58
P/S
2.09
EV / EBITDA
13.91
EV / Sales
2.92
EPS
8.3
Dividend Yield
0%
P/FCF
16.41
P/CF
12.84
Free Cash Flow
$2,116,000,000
ROE
22.26%
ROA
4.67%
Debt / Equity
2.55
Current Ratio
0.75
Quick Ratio
0.75
Cash
0.23
Avg Volume
$1,427,382
Fundamentals Snapshot Price
208.05

Income Statement

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Revenue 4.15B 4.36B 4.1B 4.02B 3.83B
Cost of revenue 2.8B 2.93B 2.73B 2.69B 2.53B
Gross profit 1.36B 1.44B 1.37B 1.32B 1.3B
Operating income 514M 627M 553M 506M 496M
EBITDA 853M 968M 859M 814M 790M
Net income 274M 514M 331M 266M 249M
Income taxes 59M 59M 76M 61M
Interest expense -192M -193M -189M -182M -165M
Other operating expenses 51M 24M 20M 32M 29M
Total operating expenses 841M 809M 820M 817M 802M
Basic EPS 1.63 3.01 1.94 1.55 1.42
Diluted EPS 1.61 2.98 1.93 1.54 1.4

Balance Sheet

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Total assets 29.68B 29.94B 28.73B 28.63B 27.32B
Total liabilities 23.33B 23.31B 22.44B 22.85B 21.34B
Total equity 6.35B 6.63B 6.29B 5.79B 5.99B
Cash & equivalents 1.95B 1.98B 1.81B 2.04B 1.74B
Current assets 6.22B 6.25B 5.98B 6.35B 5.91B
Current liabilities 8.33B 8.34B 8.51B 7.57B 7.18B
Accounts payable 3.64B 3.75B
Receivables 3.38B 3.43B 3.31B 3.96B 3.31B
Goodwill 16.54B 16.62B 15.95B 15.61B 15.03B
Long-term debt 13.99B 13.88B 12.79B 14.18B 13.11B

Cash Flow

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Operating cash flow 618M 735M 908M 443M 568M
Investing cash flow -196M -1.1B -550M -346M -305M
Financing cash flow -433M 535M -572M 145M -258M
Change in cash -33M 166M -225M 299M 38M
Net income 275M 514M 332M 266M 249M
Kind Filing Date Link
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
form 4 Form 4 — DANHAKL JOHN G View Filing
form 4 Form 4 — Fasano Jim View Filing
form 4 Form 4 — GOGGINS COLLEEN A View Filing
form 4 Form 4 — Wims Morris Leslie View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
form 4 Form 4 — DANHAKL JOHN G View Filing
form 4 Form 4 — Fasano Jim View Filing
form 4 Form 4 — GOGGINS COLLEEN A View Filing
form 4 Form 4 — Wims Morris Leslie View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
edgar index 10-Q — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
edgar index SCHEDULE 13G — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 8-K — IQVIA HOLDINGS INC. View Filing
edgar index S-8 — IQVIA HOLDINGS INC. View Filing
eight k text 8-K — 8-K View Filing
form 4 Form 4 — Burt Carol View Filing
form 4 Form 4 — DANHAKL JOHN G View Filing
form 4 Form 4 — DANHAKL JOHN G View Filing
form 4 Form 4 — Fasano Jim View Filing
form 4 Form 4 — GOGGINS COLLEEN A View Filing
form 4 Form 4 — LEONARD JOHN M View Filing
form 4 Form 4 — Kaelin William G Jr View Filing
form 4 Form 4 — Wims Morris Leslie View Filing
form 4 Form 4 — Stamps Sheila A View Filing
edgar index SCHEDULE 13G/A — IQVIA HOLDINGS INC. View Filing
edgar index DEF 14A — IQVIA HOLDINGS INC. View Filing
edgar index DEFA14A — IQVIA HOLDINGS INC. View Filing
edgar index ARS — IQVIA HOLDINGS INC. View Filing
edgar index 10-K — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
ten k section 10-K — business View Filing
ten k section 10-K — mda View Filing
ten k section 10-K — risk_factors View Filing
form 4 Form 4 — Fedock Michael J. View Filing
form 4 Form 4 — Haas Bernd View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
edgar index 4 — IQVIA HOLDINGS INC. View Filing
  • Trusted by 1M+ investors
  • Global coverage
  • Real-time market data
  • Independent & unbiased

Join thousands making smarter investment decisions.

Get started for free